Publications

Malone D, Miller B, Dean R, Arjunji R, Jensen IS, Maru B, Dabbous O. 2019. Abstract PRO10: Use of single dose gene-replacement therapy for the treatment of spinal muscular atrophy type 1: A United States payer budget impact analysis. Value in Health 22(Sup2):S336-S337; doi: 10.1016/j.jval.2019.04.1644.

Malone DC, Dean R, Miller B, Arjunji R, Feltner DE, Sproule D, Jensen IS, Maru B, Dabbous O. 2019. Abstract ND2: Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment. Value in Health 22(Sup 2):S42-S43; doi: 10.1016/j.jval.2019.04.060.

Arjunji R, Dean R, Jensen IS, Miller B, Menier M, Sproule DM, Feltner DE, Droege M, et al. 2019. Abstract PBI10: Type I spinal muscular atrophy patients treated with AVXS-101 have lower use of ventilatory support, hospitalization, and associated costs compared to those treated with nusinersen. Value in Health 22(Sup 2):S48; doi: 10.1016/j.jval.2019.04.093.

Malone DC, Dean R, Arjunji R, Jensen IS, Cyr PL, Miller B, Maru B, et al. 2019. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Pol 7(1):1601484; doi: 10.1080/20016689.2019. PMID: 31105909.

Miller B. Analysis of the fetal immunological response to diacetylmorphine and methadone using avian models. Presentation at Eastern Colleges Science Conference, Niagara University, Niagara, NY, April 2016. (Received Excellence Awards for Manuscript of Research and Oral Presentation of Research)

Miller B. Study of the immunological response to diacetylmorphine and methadone using avian model. Presentation at American Association for the Advancement of Science, Washington, DC, February 2016.

Miller B. Effects of rhodium exposure on human lymphocytes (in vitro). Presentation at Society of Environmental Toxicology and Chemistry (SETAC), Vancouver, Canada, November 2014.